What is Asthmatx, Inc. and what does it bring to Boston Scientific?

Asthmatx, Inc. is a privately held company that designs, manufactures, and markets a less-invasive, catheter-based bronchial thermoplasty procedure. This procedure is for the treatment of severe persistent asthma, a condition with significant unmet medical needs. The acquisition allows Boston Scientific to enter or expand its offerings in the respiratory care market.

When is the acquisition expected to be completed?

The closing of the acquisition is expected to be completed in the fourth quarter of 2010, pending the satisfaction of customary closing conditions.

What is bronchial thermoplasty?

Bronchial thermoplasty is a less-invasive, catheter-based procedure used to treat severe persistent asthma. It works by delivering controlled heat to the airways during three separate treatment sessions, which aims to reduce the smooth muscle surrounding the airways, potentially leading to fewer asthma exacerbations.

Does this acquisition impact Boston Scientific's financial statements immediately?

This 8-K filing announces the definitive agreement to acquire Asthmatx. The financial impact, including the purchase price and any changes to financial statements, would typically be detailed in future filings once the acquisition is completed and accounting for the transaction is finalized.

BSX 8-K SEC Disclosure — Sep 20, 2010

Summary

Boston Scientific Corporation (BSX) announced on September 20, 2010, that it has entered into a definitive agreement to acquire Asthmatx, Inc. This acquisition focuses on Asthmatx's less-invasive, catheter-based bronchial thermoplasty procedure, designed for patients suffering from severe persistent asthma. The deal is expected to close in the fourth quarter of 2010, subject to standard closing conditions. This strategic move by Boston Scientific indicates an expansion into the respiratory therapeutics market, specifically targeting a significant unmet need in severe asthma treatment. Investors should monitor the integration of Asthmatx's technology and its potential impact on BSX's future revenue streams and market position in respiratory care.

Key Highlights

1Boston Scientific to acquire Asthmatx, Inc.
2Asthmatx specializes in a less-invasive bronchial thermoplasty procedure for severe asthma.
3The acquisition aims to expand BSX's presence in the respiratory therapeutics market.
4Transaction subject to customary closing conditions.
5Closing of the acquisition is anticipated in the fourth quarter of 2010.
6A press release detailing the agreement was issued on September 20, 2010.

BOSTON SCIENTIFIC CORP 8-K Report, Corporate Update (Sep 20, 2010)

Summary

Key Highlights

Frequently Asked Questions